Wall Street analysts predict that Aratana Therapeutics, Inc. (NASDAQ:PETX) will report earnings per share of ($0.30) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aratana Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.28). Aratana Therapeutics posted earnings per share of $0.69 in the same quarter last year, which would suggest a negative year-over-year growth rate of 143.5%. The firm is scheduled to report its next earnings report after the market closes on Thursday, August 3rd.
According to Zacks, analysts expect that Aratana Therapeutics will report full year earnings of ($1.13) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($0.96). For the next financial year, analysts expect that the company will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.75) to ($0.16). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Aratana Therapeutics.
Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.34). Aratana Therapeutics had a negative return on equity of 14.95% and a negative net margin of 66.72%. The company had revenue of $3.80 million during the quarter, compared to the consensus estimate of $3.05 million. During the same quarter last year, the firm earned ($0.52) earnings per share. The company’s revenue was up 2135.3% on a year-over-year basis.
Several research analysts have commented on the company. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. BidaskClub downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Stifel Nicolaus cut their target price on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $8.00 target price on shares of Aratana Therapeutics in a research note on Sunday, May 14th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $10.00.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Aratana Therapeutics by 13.9% in the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock worth $10,211,000 after buying an additional 235,208 shares in the last quarter. Wells Fargo & Company MN raised its position in Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 203,738 shares during the last quarter. General American Investors Co. Inc. raised its position in Aratana Therapeutics by 18.0% in the second quarter. General American Investors Co. Inc. now owns 618,660 shares of the biopharmaceutical company’s stock valued at $4,473,000 after buying an additional 94,201 shares during the last quarter. Tocqueville Asset Management L.P. raised its position in Aratana Therapeutics by 56.3% in the first quarter. Tocqueville Asset Management L.P. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,325,000 after buying an additional 90,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Aratana Therapeutics by 85.7% in the first quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 59,181 shares during the last quarter. 67.55% of the stock is currently owned by institutional investors.
Aratana Therapeutics (PETX) traded down 0.89% during midday trading on Thursday, hitting $6.69. The stock had a trading volume of 278,611 shares. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $10.73. The company has a 50-day moving average price of $7.05 and a 200-day moving average price of $6.47. The stock’s market cap is $281.45 million.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with our FREE daily email newsletter.